Dimecres, 20 de de juny de 2012
XCELIA supplies the first biomedical pharmaceutical products
This Banc de Sang i Teixits’ division has begun producing pharmaceutical products to treat patients suffering from chronic knee osteoarthritis using the patient’s own stem cells. It is the first time a public corporation has manufactured pharmaceutical products for advanced cellular treatment.
XCELIA will attend BIO Boston with the Catalan delegation organised by Biocat and composed of 50 companies from the biomedical industry.
Informació relacionada
Comparteix
